Fairvalue-Calculator Fairvalue-Calculator
EN DE

Appili Therapeutics Inc (APLI) Fair Value & Analysis

Healthcare · CA · Market cap C$1.9M

PriceC$0.0150
Fair ValueC$0.0143
Upside-5.0%
Quality95/100
Evidence: Low Range C$0.0143 – C$0.0143

Fair value as of: Jun 26, 2026

Analysis

Appili Therapeutics Inc (APLI) currently trades at C$0.0150, while our model-based Fair Value estimate is C$0.0143 — implying the stock looks roughly 5.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Appili Therapeutics Inc (APLI) undervalued?
As of Jun 26, 2026, our model estimates a fair value of C$0.0143 versus a price of C$0.0150 — about −5% (overvalued). Model-based estimate, not financial advice.
What is the fair value of APLI?
Our 21-model fair value for Appili Therapeutics Inc is C$0.0143 (as of Jun 26, 2026), built from audited fundamentals. The current price is C$0.0150.
What is the quality score of APLI?
Appili Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.